Arlo-Cel - GPRC5D CAR-T: High Response Rates in Heavily Pretreated Myeloma | Susan Bal, MD

Arlo-Cel - GPRC5D CAR-T: High Response Rates in Heavily Pretreated Myeloma | Susan Bal, MD
Arlo-Cel - GPRC5D CAR-T: High Response Rates in Heavily Pretreated Myeloma | Susan Bal, MD
AURIGA Study Update on MRD Negativity Rates - (D-VRd in NDMM) | Alfred Chung, MD
AURIGA Study Update on MRD Negativity Rates - (D-VRd in NDMM) | Alfred Chung, MD
Predicting Myeloma CAR-T Side Effects Before They Happen | Julia Noll, PhD
Predicting Myeloma CAR-T Side Effects Before They Happen | Julia Noll, PhD
Finding Hidden Myeloma Using IMMunoPET Imaging Technology | Ola Landgren, MD, PhD
Finding Hidden Myeloma Using IMMunoPET Imaging Technology | Ola Landgren, MD, PhD
Bispecific Antibodies in CNS Myeloma: What Patients Should Know | Mahmoud Gaballa, MD
Bispecific Antibodies in CNS Myeloma: What Patients Should Know | Mahmoud Gaballa, MD
Real-world Data on patients being treated with teclistamab | Artur Jurczyszyn, MD
Real-world Data on patients being treated with teclistamab | Artur Jurczyszyn, MD
Living Longer With Myeloma: Real-World Clinic Results | James Berenson, MD
Living Longer With Myeloma: Real-World Clinic Results | James Berenson, MD
An Overview of the Most Recent Studies in Multiple Myeloma | Claudio Cerchione, MD, PhD
An Overview of the Most Recent Studies in Multiple Myeloma | Claudio Cerchione, MD, PhD
Daratumumab + lenalidomide vs lenalidomide as myeloma maintenance | Mitul Gandhi, MD
Daratumumab + lenalidomide vs lenalidomide as myeloma maintenance | Mitul Gandhi, MD